Allosteric modulators of the α7 nicotinic acetylcholine receptor

被引:75
作者
Faghih, Ramin [1 ]
Gopalakrishnan, Murali [1 ]
Briggs, Clark A. [1 ]
机构
[1] Abbott Labs, Global Pharmaceut Res & Dev, Abbott Pk, IL 60064 USA
关键词
D O I
10.1021/jm070256g
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
[No abstract available]
引用
收藏
页码:701 / 712
页数:12
相关论文
共 191 条
[61]   Brain nicotinic acetylcholine receptors: native subtypes and their relevance [J].
Gotti, Cecilia ;
Zoli, Michele ;
Clementi, Francesco .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2006, 27 (09) :482-491
[62]  
GRANTHAM CJ, 2004, SOC NEUR ABSTR, V30
[63]   Hippocampal synaptic transmission enhanced by low concentrations of nicotine [J].
Gray, R ;
Rajan, AS ;
Radcliffe, KA ;
Yakehiro, M ;
Dani, JA .
NATURE, 1996, 383 (6602) :713-716
[64]   Distinct profiles of α7 nAChR positive allosteric modulation revealed by structurally diverse chemotypes [J].
Gronlien, Jens Halvard ;
Hakerud, Monika ;
Ween, Hilde ;
Thorin-Hagene, Kirsten ;
Briggs, Clark A. ;
Gopalakrishnan, Murali ;
Malysz, John .
MOLECULAR PHARMACOLOGY, 2007, 72 (03) :715-724
[65]   Effect of subtype selective nicotinic compounds on attention as assessed by the five-choice serial reaction time task [J].
Grottick, AJ ;
Higgins, GA .
BEHAVIOURAL BRAIN RESEARCH, 2000, 117 (1-2) :197-208
[66]  
Grottick AJ, 2000, J PHARMACOL EXP THER, V294, P1112
[67]   The selective α7 nicotinic acetylcholine receptor agonist PNU-282987[N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide hydrochloride] enhances GABAergic synaptic activity in brain slices and restores auditory gating deficits in anesthetized rats [J].
Hajós, M ;
Hurst, RS ;
Hoffmann, WE ;
Krause, M ;
Wall, TM ;
Higdon, NR ;
Groppi, VE .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 312 (03) :1213-1222
[68]   Targeting information-processing deficit in schizophrenia:: a novel approach to psychotherapeutic drug discovery [J].
Hajos, Mihaly .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2006, 27 (07) :391-398
[69]  
Hall D. A., 2006, Allosteric receptor modulation in drug targeting, P39, DOI [10.1201/9781420016185.ch3, DOI 10.1201/9781420016185.CH3]
[70]  
Hanna ST, 2006, J CARDIOVASC PHARM, V47, P348